Nucleoside-lipid-based nanocarriers for methylene blue delivery: potential application as anti-malarial drug
Nucleolipid supramolecular assemblies are promising Drug Delivery Systems (DDS), particularly for nucleic acids. Studies based on negatively and positively charged nucleolipids (diC16dT and DOTAU, respectively) demonstrated appropriate stability, safety, and purity profile to be used as DDS. Methyle...
Gespeichert in:
Veröffentlicht in: | RSC advances 2019-06, Vol.9 (33), p.18844-18852 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 18852 |
---|---|
container_issue | 33 |
container_start_page | 18844 |
container_title | RSC advances |
container_volume | 9 |
creator | Kowouvi, Koffi Alies, Bruno Gendrot, Mathieu Gaubert, Alexandra Vacher, Gaelle Gaudin, Karen Mosnier, Joel Pradines, Bruno Barthelemy, Philippe Grislain, Luc Millet, Pascal |
description | Nucleolipid supramolecular assemblies are promising Drug Delivery Systems (DDS), particularly for nucleic acids. Studies based on negatively and positively charged nucleolipids (diC16dT and DOTAU, respectively) demonstrated appropriate stability, safety, and purity profile to be used as DDS. Methylene Blue (MB) remains a good antimalarial drug candidate, and could be considered for the treatment of uncomplicated or severe malaria. However, the development of MB as an antimalarial drug has been hampered by a high dose regimen required to obtain a proper effect, and a short plasmatic half life. We demonstrated that nanoparticles formed by nucleolipid encapsulation of MB using diC16dT and DOTAU (MB-NPs) is an interesting approach to improve drug stability and delivery. MB-NPs displayed sizes, PDI, zeta values, and colloidal stability allowing a possible use in intravenous formulations. Nanoparticles partially protected MB from oxido-reduction reactions, thus preventing early degradation during storage, and allowing prolongated pharmacokinetic in plasma. MB-NPs' efficacy, tested
in vitro
on sensitive or multidrug resistant strains of
Plasmodium falciparum
, was statistically similar to MB alone, with a slightly lower IC
50
. This nucleolipid-based approach to protect drugs against degradation represents a new alternative tool to be considered for malaria treatment.
Nucleolipids protects methylene blue against reduction (induced by light and chemical reductants) and do not impair antimalarial activity. |
doi_str_mv | 10.1039/c9ra02576f |
format | Article |
fullrecord | <record><control><sourceid>proquest_rsc_p</sourceid><recordid>TN_cdi_proquest_journals_2246706148</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2661084242</sourcerecordid><originalsourceid>FETCH-LOGICAL-c529t-38326d3ae45f6fea1eb6e97d2db9ce0b08faf7001569984f5feb42a24f01aa0b3</originalsourceid><addsrcrecordid>eNp9ksFvFCEUxidGY5vai3fNGC_WZBQYhh08mGw2rTXZaGL0TN7Ao0vDDCPMbLL_vaxb19qDXCDv-_Hx4KMonlPyjpJavtcyAmHNQthHxSkjXFSMCPn43vqkOE_pluQhGsoEfVqc1E1DRdvy08J_mbXHkJzByrvRmaqDhKYcYAgaYnQYU2lDLHucNjuPA5adn7E06N0W4-5DOYYJh8mBL2EcvdMwuTCUkErI1aoHD3EvmjjfPCueWPAJz-_ms-LH1eX31XW1_vrp82q5rnTD5FTVbc2EqQF5Y4VFoNgJlAvDTCc1ko60FuyCENoIKVtuG4sdZ8C4JRSAdPVZ8fHgO85dj0bn_iJ4NUbXQ9ypAE79qwxuo27CVkkiuBQ0G1wcDDYPtl0v12pfI4yKpl3I7Z59c3dYDD9nTJPqXdLoPQwY5qSYEJS0nHGW0dcP0NswxyE_hWKMiwURlLeZenugdAwpRbTHDihR-8zVSn5b_s78KsMv71_1iP5JOAMvDkBM-qj-_TRZf_U_XY3G1r8A4Oe-Fw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2246706148</pqid></control><display><type>article</type><title>Nucleoside-lipid-based nanocarriers for methylene blue delivery: potential application as anti-malarial drug</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Kowouvi, Koffi ; Alies, Bruno ; Gendrot, Mathieu ; Gaubert, Alexandra ; Vacher, Gaelle ; Gaudin, Karen ; Mosnier, Joel ; Pradines, Bruno ; Barthelemy, Philippe ; Grislain, Luc ; Millet, Pascal</creator><creatorcontrib>Kowouvi, Koffi ; Alies, Bruno ; Gendrot, Mathieu ; Gaubert, Alexandra ; Vacher, Gaelle ; Gaudin, Karen ; Mosnier, Joel ; Pradines, Bruno ; Barthelemy, Philippe ; Grislain, Luc ; Millet, Pascal</creatorcontrib><description>Nucleolipid supramolecular assemblies are promising Drug Delivery Systems (DDS), particularly for nucleic acids. Studies based on negatively and positively charged nucleolipids (diC16dT and DOTAU, respectively) demonstrated appropriate stability, safety, and purity profile to be used as DDS. Methylene Blue (MB) remains a good antimalarial drug candidate, and could be considered for the treatment of uncomplicated or severe malaria. However, the development of MB as an antimalarial drug has been hampered by a high dose regimen required to obtain a proper effect, and a short plasmatic half life. We demonstrated that nanoparticles formed by nucleolipid encapsulation of MB using diC16dT and DOTAU (MB-NPs) is an interesting approach to improve drug stability and delivery. MB-NPs displayed sizes, PDI, zeta values, and colloidal stability allowing a possible use in intravenous formulations. Nanoparticles partially protected MB from oxido-reduction reactions, thus preventing early degradation during storage, and allowing prolongated pharmacokinetic in plasma. MB-NPs' efficacy, tested
in vitro
on sensitive or multidrug resistant strains of
Plasmodium falciparum
, was statistically similar to MB alone, with a slightly lower IC
50
. This nucleolipid-based approach to protect drugs against degradation represents a new alternative tool to be considered for malaria treatment.
Nucleolipids protects methylene blue against reduction (induced by light and chemical reductants) and do not impair antimalarial activity.</description><identifier>ISSN: 2046-2069</identifier><identifier>EISSN: 2046-2069</identifier><identifier>DOI: 10.1039/c9ra02576f</identifier><identifier>PMID: 35516884</identifier><language>eng</language><publisher>England: Royal Society of Chemistry</publisher><subject>Chemical reduction ; Chemistry ; Degradation ; Drug delivery systems ; Formulations ; Life Sciences ; Lipids ; Malaria ; Methylene blue ; Microbiology and Parasitology ; Nanoparticles ; Nucleic acids ; Parasitology ; Pharmacology ; Stability</subject><ispartof>RSC advances, 2019-06, Vol.9 (33), p.18844-18852</ispartof><rights>This journal is © The Royal Society of Chemistry.</rights><rights>Copyright Royal Society of Chemistry 2019</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>This journal is © The Royal Society of Chemistry 2019 The Royal Society of Chemistry</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c529t-38326d3ae45f6fea1eb6e97d2db9ce0b08faf7001569984f5feb42a24f01aa0b3</citedby><cites>FETCH-LOGICAL-c529t-38326d3ae45f6fea1eb6e97d2db9ce0b08faf7001569984f5feb42a24f01aa0b3</cites><orcidid>0000-0002-4935-1747 ; 0000-0003-3917-0579 ; 0000-0001-8360-3496 ; 0000-0002-2322-5427 ; 0000-0002-0755-145X ; 0000-0002-2360-3803</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064961/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064961/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35516884$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02165879$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Kowouvi, Koffi</creatorcontrib><creatorcontrib>Alies, Bruno</creatorcontrib><creatorcontrib>Gendrot, Mathieu</creatorcontrib><creatorcontrib>Gaubert, Alexandra</creatorcontrib><creatorcontrib>Vacher, Gaelle</creatorcontrib><creatorcontrib>Gaudin, Karen</creatorcontrib><creatorcontrib>Mosnier, Joel</creatorcontrib><creatorcontrib>Pradines, Bruno</creatorcontrib><creatorcontrib>Barthelemy, Philippe</creatorcontrib><creatorcontrib>Grislain, Luc</creatorcontrib><creatorcontrib>Millet, Pascal</creatorcontrib><title>Nucleoside-lipid-based nanocarriers for methylene blue delivery: potential application as anti-malarial drug</title><title>RSC advances</title><addtitle>RSC Adv</addtitle><description>Nucleolipid supramolecular assemblies are promising Drug Delivery Systems (DDS), particularly for nucleic acids. Studies based on negatively and positively charged nucleolipids (diC16dT and DOTAU, respectively) demonstrated appropriate stability, safety, and purity profile to be used as DDS. Methylene Blue (MB) remains a good antimalarial drug candidate, and could be considered for the treatment of uncomplicated or severe malaria. However, the development of MB as an antimalarial drug has been hampered by a high dose regimen required to obtain a proper effect, and a short plasmatic half life. We demonstrated that nanoparticles formed by nucleolipid encapsulation of MB using diC16dT and DOTAU (MB-NPs) is an interesting approach to improve drug stability and delivery. MB-NPs displayed sizes, PDI, zeta values, and colloidal stability allowing a possible use in intravenous formulations. Nanoparticles partially protected MB from oxido-reduction reactions, thus preventing early degradation during storage, and allowing prolongated pharmacokinetic in plasma. MB-NPs' efficacy, tested
in vitro
on sensitive or multidrug resistant strains of
Plasmodium falciparum
, was statistically similar to MB alone, with a slightly lower IC
50
. This nucleolipid-based approach to protect drugs against degradation represents a new alternative tool to be considered for malaria treatment.
Nucleolipids protects methylene blue against reduction (induced by light and chemical reductants) and do not impair antimalarial activity.</description><subject>Chemical reduction</subject><subject>Chemistry</subject><subject>Degradation</subject><subject>Drug delivery systems</subject><subject>Formulations</subject><subject>Life Sciences</subject><subject>Lipids</subject><subject>Malaria</subject><subject>Methylene blue</subject><subject>Microbiology and Parasitology</subject><subject>Nanoparticles</subject><subject>Nucleic acids</subject><subject>Parasitology</subject><subject>Pharmacology</subject><subject>Stability</subject><issn>2046-2069</issn><issn>2046-2069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9ksFvFCEUxidGY5vai3fNGC_WZBQYhh08mGw2rTXZaGL0TN7Ao0vDDCPMbLL_vaxb19qDXCDv-_Hx4KMonlPyjpJavtcyAmHNQthHxSkjXFSMCPn43vqkOE_pluQhGsoEfVqc1E1DRdvy08J_mbXHkJzByrvRmaqDhKYcYAgaYnQYU2lDLHucNjuPA5adn7E06N0W4-5DOYYJh8mBL2EcvdMwuTCUkErI1aoHD3EvmjjfPCueWPAJz-_ms-LH1eX31XW1_vrp82q5rnTD5FTVbc2EqQF5Y4VFoNgJlAvDTCc1ko60FuyCENoIKVtuG4sdZ8C4JRSAdPVZ8fHgO85dj0bn_iJ4NUbXQ9ypAE79qwxuo27CVkkiuBQ0G1wcDDYPtl0v12pfI4yKpl3I7Z59c3dYDD9nTJPqXdLoPQwY5qSYEJS0nHGW0dcP0NswxyE_hWKMiwURlLeZenugdAwpRbTHDihR-8zVSn5b_s78KsMv71_1iP5JOAMvDkBM-qj-_TRZf_U_XY3G1r8A4Oe-Fw</recordid><startdate>20190617</startdate><enddate>20190617</enddate><creator>Kowouvi, Koffi</creator><creator>Alies, Bruno</creator><creator>Gendrot, Mathieu</creator><creator>Gaubert, Alexandra</creator><creator>Vacher, Gaelle</creator><creator>Gaudin, Karen</creator><creator>Mosnier, Joel</creator><creator>Pradines, Bruno</creator><creator>Barthelemy, Philippe</creator><creator>Grislain, Luc</creator><creator>Millet, Pascal</creator><general>Royal Society of Chemistry</general><general>The Royal Society of Chemistry</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SR</scope><scope>8BQ</scope><scope>8FD</scope><scope>JG9</scope><scope>7X8</scope><scope>1XC</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4935-1747</orcidid><orcidid>https://orcid.org/0000-0003-3917-0579</orcidid><orcidid>https://orcid.org/0000-0001-8360-3496</orcidid><orcidid>https://orcid.org/0000-0002-2322-5427</orcidid><orcidid>https://orcid.org/0000-0002-0755-145X</orcidid><orcidid>https://orcid.org/0000-0002-2360-3803</orcidid></search><sort><creationdate>20190617</creationdate><title>Nucleoside-lipid-based nanocarriers for methylene blue delivery: potential application as anti-malarial drug</title><author>Kowouvi, Koffi ; Alies, Bruno ; Gendrot, Mathieu ; Gaubert, Alexandra ; Vacher, Gaelle ; Gaudin, Karen ; Mosnier, Joel ; Pradines, Bruno ; Barthelemy, Philippe ; Grislain, Luc ; Millet, Pascal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c529t-38326d3ae45f6fea1eb6e97d2db9ce0b08faf7001569984f5feb42a24f01aa0b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Chemical reduction</topic><topic>Chemistry</topic><topic>Degradation</topic><topic>Drug delivery systems</topic><topic>Formulations</topic><topic>Life Sciences</topic><topic>Lipids</topic><topic>Malaria</topic><topic>Methylene blue</topic><topic>Microbiology and Parasitology</topic><topic>Nanoparticles</topic><topic>Nucleic acids</topic><topic>Parasitology</topic><topic>Pharmacology</topic><topic>Stability</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kowouvi, Koffi</creatorcontrib><creatorcontrib>Alies, Bruno</creatorcontrib><creatorcontrib>Gendrot, Mathieu</creatorcontrib><creatorcontrib>Gaubert, Alexandra</creatorcontrib><creatorcontrib>Vacher, Gaelle</creatorcontrib><creatorcontrib>Gaudin, Karen</creatorcontrib><creatorcontrib>Mosnier, Joel</creatorcontrib><creatorcontrib>Pradines, Bruno</creatorcontrib><creatorcontrib>Barthelemy, Philippe</creatorcontrib><creatorcontrib>Grislain, Luc</creatorcontrib><creatorcontrib>Millet, Pascal</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Engineered Materials Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Materials Research Database</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>RSC advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kowouvi, Koffi</au><au>Alies, Bruno</au><au>Gendrot, Mathieu</au><au>Gaubert, Alexandra</au><au>Vacher, Gaelle</au><au>Gaudin, Karen</au><au>Mosnier, Joel</au><au>Pradines, Bruno</au><au>Barthelemy, Philippe</au><au>Grislain, Luc</au><au>Millet, Pascal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nucleoside-lipid-based nanocarriers for methylene blue delivery: potential application as anti-malarial drug</atitle><jtitle>RSC advances</jtitle><addtitle>RSC Adv</addtitle><date>2019-06-17</date><risdate>2019</risdate><volume>9</volume><issue>33</issue><spage>18844</spage><epage>18852</epage><pages>18844-18852</pages><issn>2046-2069</issn><eissn>2046-2069</eissn><abstract>Nucleolipid supramolecular assemblies are promising Drug Delivery Systems (DDS), particularly for nucleic acids. Studies based on negatively and positively charged nucleolipids (diC16dT and DOTAU, respectively) demonstrated appropriate stability, safety, and purity profile to be used as DDS. Methylene Blue (MB) remains a good antimalarial drug candidate, and could be considered for the treatment of uncomplicated or severe malaria. However, the development of MB as an antimalarial drug has been hampered by a high dose regimen required to obtain a proper effect, and a short plasmatic half life. We demonstrated that nanoparticles formed by nucleolipid encapsulation of MB using diC16dT and DOTAU (MB-NPs) is an interesting approach to improve drug stability and delivery. MB-NPs displayed sizes, PDI, zeta values, and colloidal stability allowing a possible use in intravenous formulations. Nanoparticles partially protected MB from oxido-reduction reactions, thus preventing early degradation during storage, and allowing prolongated pharmacokinetic in plasma. MB-NPs' efficacy, tested
in vitro
on sensitive or multidrug resistant strains of
Plasmodium falciparum
, was statistically similar to MB alone, with a slightly lower IC
50
. This nucleolipid-based approach to protect drugs against degradation represents a new alternative tool to be considered for malaria treatment.
Nucleolipids protects methylene blue against reduction (induced by light and chemical reductants) and do not impair antimalarial activity.</abstract><cop>England</cop><pub>Royal Society of Chemistry</pub><pmid>35516884</pmid><doi>10.1039/c9ra02576f</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-4935-1747</orcidid><orcidid>https://orcid.org/0000-0003-3917-0579</orcidid><orcidid>https://orcid.org/0000-0001-8360-3496</orcidid><orcidid>https://orcid.org/0000-0002-2322-5427</orcidid><orcidid>https://orcid.org/0000-0002-0755-145X</orcidid><orcidid>https://orcid.org/0000-0002-2360-3803</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2046-2069 |
ispartof | RSC advances, 2019-06, Vol.9 (33), p.18844-18852 |
issn | 2046-2069 2046-2069 |
language | eng |
recordid | cdi_proquest_journals_2246706148 |
source | DOAJ Directory of Open Access Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Chemical reduction Chemistry Degradation Drug delivery systems Formulations Life Sciences Lipids Malaria Methylene blue Microbiology and Parasitology Nanoparticles Nucleic acids Parasitology Pharmacology Stability |
title | Nucleoside-lipid-based nanocarriers for methylene blue delivery: potential application as anti-malarial drug |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T21%3A21%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_rsc_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nucleoside-lipid-based%20nanocarriers%20for%20methylene%20blue%20delivery:%20potential%20application%20as%20anti-malarial%20drug&rft.jtitle=RSC%20advances&rft.au=Kowouvi,%20Koffi&rft.date=2019-06-17&rft.volume=9&rft.issue=33&rft.spage=18844&rft.epage=18852&rft.pages=18844-18852&rft.issn=2046-2069&rft.eissn=2046-2069&rft_id=info:doi/10.1039/c9ra02576f&rft_dat=%3Cproquest_rsc_p%3E2661084242%3C/proquest_rsc_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2246706148&rft_id=info:pmid/35516884&rfr_iscdi=true |